Business
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
Met the primary endpoint, achieving statistically significant 68%
About this update from Apellis Pharmaceuticals, Inc.
[{"type":"text","content":"Met the primary endpoint, achieving statistically significant 68% (p","length":105,"tagName":"div"}]